Pharmaceutical firm Immunomedics will bring its LeukoScan contrast agent to Australia. The Australian Drug Evaluation Committee has recommended approval for imaging of suspected osteomyelitis in long bones and feet, including those with diabetic foot ulcers, according to the Morris Plains, NJ-based vendor. Immunomedics partner Australian Radioisotopes will handle marketing and distribution.
By AuntMinnie.com staff writersMarch 7, 2002
Related Reading
Immunomedics doubles revenue, trims loss, November 9, 2001
Immunomedics licenses labeling method, October 29, 2001
Immunomedics trims loss in 2001, August 8, 2001
Immunomedics appoints Sullivan CEO, March 21, 2001
Copyright © 2002 AuntMinnie.com